3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Completed
18
Recruiting
5
Terminated
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
10
Esophageal Neoplasms
4
Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Oesophago-gastric Cancer
1
KRAS and NRAS Wild-type Colorectal Cancer
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Cone Dystrophy 3
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Breast Neoplasms
1
Advanced Colorectal Cancer
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
pembrolizumab
30
Capecitabine
24
Bevacizumab
23
Cyclophosphamide
22
Gemcitabine
21
Paclitaxel
20
Nivolumab
19
Fluorouracil
19
Docetaxel
18
aldesleukin
17
Leucovorin
17
Irinotecan
17
Oxaliplatin
15
Interleukin-2
14
Radiosurgery
13
Cisplatin
13
Cetuximab
13
fludarabine
12
Carboplatin
12
Albumin-Bound Paclitaxel
11
fludarabine phosphate
10
Ipilimumab
10
Drug Therapy
10
Doxorubicin
10
Sunitinib
9
Radiotherapy
9
Everolimus
9
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
Temozolomide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm Metastasis
×
Panitumumab
×
Clear all
NCT02015923
2021-03-16
CCRe-IV
Hospital Universitari de Bellvitge
Phase 4
Terminated
107 enrolled
NCT00950820
2013-03-04
VOXEL
AIO-Studien-gGmbH
Phase 2
Terminated
9 enrolled